ARTICLE | Company News

Roche submits CERA BLA

April 21, 2006 12:55 AM UTC

Roche (SWX:ROCZ) submitted a BLA for its Continuous Erythropoiesis Receptor Activator (CERA) to treat anemia associated with chronic kidney disease (CKD). The compound is a single methoxy-polyethylene glycol polymer bound to an EPO molecule. ROCZ's news did not put pressure on shares of Amgen (AMGN) on Thursday. AMGN, which sells EPO drugs Epogen and second generation drug Aranesp, was up $0.21 to $68.51. ...